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Abstract
Purpose Hyperkalaemia due to potassium-increasing drug–
drug interactions (DDIs) is a clinically important adverse drug
event. The purpose of this study was to identify patient- and
physician-related risk factors for the development of
hyperkalaemia.
Methods The risk for adult patients hospitalised in the
University Hospital Zurich between 1 December 2009 and
31 December 2011 of developing hyperkalaemia was
correlated with patient characteristics, number, type and
duration of potassium-increasing DDIs and frequency of
serum potassium monitoring.
Results The 76,467 patients included in this study were
prescribed 8,413 potentially severe potassium-increasing
DDIs. Patient-related characteristics associated with the
development of hyperkalaemia were pulmonary allograft
[relative risk (RR) 5.1; p <0.0001), impaired renal function
(RR 2.7; p <0.0001), diabetes mellitus (RR 1.6; p =0.002) and
female gender (RR 1.5; p =0.007). Risk factors associated
with medication were number of concurrently administered
potassium-increasing drugs (RR 3.3 per additional drug; p <
0.0001) and longer duration of the DDI (RR 4.9 for duration
≥6 days; p <0.0001). Physician-related factors associated with
the development of hyperkalaemia were undetermined or
elevated serum potassium level before treatment initiation
(RR 2.2; p <0.001) and infrequent monitoring of serum
potassium during a DDI (interval >48 h: RR 1.6; p <0.01).
Conclusion Strategies for reducing the risk of hyperkalaemia
during potassium-increasing DDIs should consider both
patient- and physician-related risk factors.
Keywords Drug–drug interactions . Hyperkalaemia .
Monitoring . Potassium . Risk factors
Introduction
Although drug–drug interactions (DDIs) are often preventable,
they constitute an important cause of adverse drug events
leading to increased morbidity and mortality [1–3].
Potassium-increasingDDIs are among themost commonDDIs,
occurring in up to 10 % of hospitalised patients [4, 5]. Such
DDIs may induce hyperkalaemia and life-threatening cardiac
arrhythmias [6].
It is a challenge for physicians to identify potentially harmful
potassium-increasing DDIs due to polypharmacy and the
increasing number of therapeutic agents. Computerized
physician order entry (CPOE) technology in combination with
clinical decision support systems (CDSS) may help the
prescribing physician(s) to detect DDIs and alerts them to a
potential problem. However, these systems are often based on
DDI knowledge databases which do not take patient
characteristics into account, resulting in a low specificity of
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alerts, overalerting and alert fatigue [7–10]. In order to
avoid alert fatigue the University Hospital Zurich has
implemented on-demand DDI checks into the electronic
health record [11].
Several published studies have analysed the risk factors for
developing hyperkalaemia during potassium-increasing
DDIs, with a focus on patient-related risk factors, such as
demographic parameters and comorbidities, and on
medication, such as number and types of drugs involved
[12–18]. One study considered the effect of potassium
monitoring during potassium-increasing DDIs in outpatients
[19]. To our knowledge, no study has as yet investigated the
effect of physician-related risk factors, such as missing serum
potassium measurement at the start of therapy and periodicity
of serum potassium monitoring during drug therapy in
hospitalised patients.
The purpose of this study was to identify patient- and
physician-related risk factors for the development of
hyperkalaemia. Such information may provide a foundation
for the implementation of strategies for reducing the risk of
hyperkalaemia during potassium-increasing DDIs without
overalerting.
Methods
Setting
The University Hospital Zurich is a publicly owned, tertiary
care academic medical centre with 850 beds and 35,000
hospital admissions per year. We included all in-patients from
1 December 2009 to 31 December 2011 except for patients on
dialysis and those hospitalized exclusively in intensive care
units.
The local research ethics committee approved the analyses,
and patient consent was waived.
Drug–drug interactions and potassium-increasing drugs
Drug–drug interactions were identified using the knowledge
base galdat/hospINDEX (distributed by e-mediat AG, Berne,
Switzerland—derived fromABDATA Pharma-Daten Service,
Werbe- und Vertriebsgesellschaft Deutscher Apotheker,
Eschborn, Germany), which tiers DDIs by severity (severity
level 1: recommended activity ‘contraindicated’; 2:
‘contraindicated as precaution‘,3: ‘monitoring or adaptation
required’, 4: ‘monitoring or adaption in case of risk factors’, 5:
‘monitoring as a precaution’, 6: ‘no activity required’) [20].
DDIs with severity levels 1 to 3 were considered to be severe.
Potassium-increasing drugs (PIDs) were defined as drugs
involved in severe potassium-increasing DDIs according to
the knowledge base galdat/hospINDEX. Thus, PIDs included
angiotensin-converting enzyme inhibitors (ACE inhibitors),
angiotensin antagonists (angiotensin-receptor blockers), direct
renin inhibitors, immunosuppressive agents (calcineurin
inhibitors), potassium-sparing diuretics (aldosterone-receptor
antagonists and epithelial sodium channel blockers),
potassium supplements and trimethoprim (ingredient of
cotrimoxazole), irrespective of whether these drugs were
ordered as a monotherapy or participated in a DDI.
Serum potassium measurements
Serum potassium levels were categorized into four groups: (1)
hypokalaemia: serum potassium ≤3.2 mEq/l [21]; (2)
reference range: ≥3.3 mEq/l to ≤4.5 mEq/l [22]; (3)
moderately increased: ≥4.6 mEq/l to ≤5.4 mEq/l; (4)
hyperkalaemia: ≥5.5 mEq/l [12].
The following parameters, explored for their association
with hyperkalaemia, need to be defined:
(1) Estimated glomerular filtration rate (GFR) was
calculated using the Cockcroft–Gault equation [23] with
the first serum creatinine level measured during DDI±
1 day. The kidney dysfunction categories ‘normal’,
‘mild’ and ‘moderate to severe’ were assigned to a
GFR of ≥90 ml/min, 60 ml/min ≤ GFR < 90 ml/min
and GFR <60 ml/min, respectively [24].
(2) Blood transfusions were identified by ICD-9 (International
Classification of Diseases, World Health Organization,
Geneva, Switzerland) treatment code 99.0.
(3) Comorbidities were identified using ICD-10 discharge
diagnosis codes E10, E11, E12, E13, and E14 for
diabetesmellitus, code I10 for arterial hypertension, code
I50 for heart failure, codes I50.11 and I50.12 for NYHA
class I/II, codes I50.13 and I50.14 for NYHA class III/IV
and code Z94.2 for pulmonary allograft.
Statistical analyses
Data analyses and statistical tests were performed using the R
language and environment for statistical computing, version
2.15.1 (R Foundation for Statistical Computing, Vienna,
Austria). p levels of ≤0.05 were considered to be statistically
significant. The two-tailed chi-square test was used to analyse
categorical data of 2×2 contingency tables. p levels for
multiple comparisons were adjusted using the Holm
correction [25]. Binomial confidence intervals were calculated
using the Clopper–Pearson method [26].
Results
We analysed data of 76,467 inpatients. Mean duration of
hospitalisation for all patients and for patients with potassium-
increasing DDIs was 6.9 and 13.5 days, respectively. Patients’
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characteristics are listed in the Electronic Supplementary
Material (ESM) 1.
A total of 1,543,578 drugs were prescribed, resulting in 20.1
drugs per patient on average. PIDs accounted for 5.0 % of all
drug prescriptions. Potassium supplements were the most
frequently ordered PIDs (30 % of all PID prescriptions),
followed by immunosuppressive agents (21%), ACE inhibitors
(20 %), angiotensin antagonists (14 %), trimethoprim (9 %),
potassium-sparing diuretics (6 %) and direct renin inhibitors
(0.3 %).
Drug–drug interactions
We identified 197,351 potential DDIs (2.6 per patient) in the
included patients, of which 90,811 were classified as severe
(1.2 per patient). The 8,413 potassium-increasing DDIs
constituted the largest part of level-1 DDIs (972 of 1,402
DDIs) and also played an important role in level-3 DDIs (7,
441 of 84,093 DDIs).
In 17 % of the potassium-increasing DDIs, treatment
had been started in the absence of a serum potassium
measurement within the preceding 48 h. Moreover, 60
potassium-increasing DDIs (0.7 %) were initiated despite the
presence of hyperkalaemia. The histogram of the last serum
potassium levels measured within 48 h prior to a potassium-
increasing DDI shows a bimodal distribution (Fig. 1), with
one peak in the hypokalaemic range and another one in the
reference range. Most of the therapies that were started with
the patient in the hypokalaemic range included a potassium
supplement, suggesting that these therapies were purposely
prescribed to correct the low potassium level.
The frequency of daily serum potassium level measurements
decreased from 72 % on the day before the DDI to 59 % on the
first day of the DDI and remained between 46 and 53 % during
the next 2 weeks (the frequencies per day are shown in ESM 2).
The intervals between serum level measurements during
potassium-increasing DDIs showed a wide range (median
interval 24 h) with 84.8 % of the serum level measurements
embedded in intervals of ≤48 h. Thus, 15.2 % of the
monitoring intervals exceeded 48 h (the frequency distribution
of serum potassiummonitoring intervals is presented in ESM 3).
Similar monitoring frequencies were observed in surgical and
non-surgical specialties, with the median monitoring period in
both groups being 1.0 days. In surgical specialties the
monitoring intervals exceeded 48 and 96 h in 14.3 and
2.3 % of DDIs, respectively; in non-surgical specialties the
respective numbers were 15.6 and 2.5 %.
Hyperkalaemia
The occurrences of hyperkalaemia were analysed after the
exclusion of DDIs started in the presence of hyperkalaemia
(60 DDIs in 28 patients), leaving 8,353 potassium-increasing
DDIs in 5,609 patients for further analysis. Hyperkalaemia
was observed during 161 DDIs involving 78 patients. A
further increased serum potassium level of >6.0 mEq/l
occurred during 31 DDIs observed in 15 patients.
Two physician-related risk factors for hyperkalaemia
were the consideration of the initial serum potassium level
and the serum potassium monitoring frequency. First, the
initiation of a potassium-increasing DDI with either an
undetermined or an elevated (>4.5 mEq/l) serum potassium
level (2,252 DDIs, 71 with hyperkalaemia during DDI) was
associated with an increased relative risk (RR) of 2.2 of
developing hyperkalaemia, compared to starting a DDI at
normokalaemic or hypokalaemic levels (6,101 DDIs, 90
with hyperkalaemia during DDI; chi-square test p <0.001).
Second, monitoring intervals exceeding 48 h during the
interaction period were associated with a higher risk of
hyperkalaemia: a new hyperkalaemia event was detected
in 1.00 % (36 out of 3,635) of the serum potassium levels
measured more than 48 h after the preceding measurement,
compared to 0.61 % (122 out of 20,092) when levels were
measured within 48 h (chi-square test: p <0.01). Three
medication factors were associated with the development
of hyperkalaemia:
(1) The higher the number of PIDs concurrently administered,
the higher the risk for hyperkalaemia (Table 1). Starting
with a RR of 1 for patients without PIDs, the RR increased
to 3.9 for PID monotherapies (chi-square test: p<0.001)
and 5.7 for therapies with two concurrent PIDs (p=0.040),
peaking at 18.1 for three or more concurrent PIDs (p<
0.001). The triple PID combination of immunosuppressive
agents + trimethoprim + ACE inhibitor achieved the
serum potasium level [mEq/l]
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highest RR of 29. Nevertheless, the absolute risk was low,
with hyperkalaemia occurrences of 0.7, 1.0 and 3.3 % for
patients treated with one, two or more than two PIDs,
respectively.
(2) The duration of potassium-increasing DDIs was
significantly associated with hyperkalaemia (Table 2).
(3) A high number of concurrently administered potassium-
decreasing drugs were associated with a higher risk of
hyperkalaemia (Table 2). Blood transfusions showed a
non-significant trend towards an increased risk of
hyperkalaemia.
Five out of seven electronically available patient-related
characteristics predicted the development of hyperkalaemia in
a univariate analysis (Table 2): (1) female gender, (2) renal
impairment, (3) diabetes mellitus, (4) pulmonary allograft and
(5) serum potassium level exceeding the normokalaemic
range before onset of potassium-increasing DDI.
The effect of renal impairment on the risk of hyperkalaemia
was analysed in greater detail as a function of the number of
concurrently administered PIDs (Fig. 2). The risk significantly
increased for patients with moderate to severe kidney
impairment compared to patients with mild kidney impairment.
Hyperkalaemia observed during potassium-increasing DDIs
was associated with a significantly increased risk of transfer
to the intensive care unit (ICU) or death (Table 3). The risk of
death within 2 days after detecting hyperkalaemia was 5.3-fold
higher than that for non-hyperkalaemic patients also treated
with concurrent PIDs. The likelihood of being transferred to
the ICU was 1.9-fold higher for hyperkalaemic patients than
for non-hyperkalaemic ones. Furthermore, the length of
hospitalisation increased significantly for patients with
hyperkalaemia during potassium-increasing DDIs.
Discussion
A number of patient- and physician-related factors have been
analysed to identify characteristics associated with the
development of hyperkalaemia during potassium-increasing
DDIs.
The results of this study demonstrate that physician-related
factors affect the risk for developing hyperkalaemia in
hospitalised patients. First, less frequent monitoring of serum
potassium during DDI was associated with an increased risk
of hyperkalaemia, likely because the rapid development of
hyperkalaemia may be missed with longer monitoring
intervals [27] and subsequent therapy adjustments may be
delayed. Among our patient cohort, the frequency of serum
potassium level measurements decreased after the first day of
DDI (as shown in ESM 2), despite the finding that the risk of
hyperkalaemia increasedwith a longer DDI duration (Table 2).
Secondly, the lack of serum level monitoring at onset of
potassium-increasing DDIs correlated with an increased risk
for developing hyperkalaemia (Table 2). This association has
been reported in a previous study on outpatients [19].
Medication also affected the risk for hyperkalaemia. As
expected, the risk for hyperkalaemia increased with the
number of concurrently administered PIDs. Surprisingly, the
risk of hyperkalaemia also rose with a growing number of
concurrent potassium-decreasing drugs. A possible
explanation for this finding might be that potassium-
decreasing drugs were used to correct higher serum potassium
Table 1 Occurrences of hyperkalaemia as a function of concurrent
administration of potassium-increasing drugs
Therapy Hyperkalaemia
No. of concurrent PID administrations
and PIDs involved in concurrent
administrations
Total no. of
patientsa
No. of
patients
Per
total
No PID administration 30,723 56 0.2 %
PID monotherapyb 17,010 122 0.7 %
Concurrent administration of 2 PIDs 4,221e 44 1.0 %
ACE inhibitor or angiotensin
antagonist + potassium supplement
2,311 24 1.0 %
ACE inhibitor or angiotensin
antagonist + potassium-sparing
diuretic
824 9 1.1 %
Trimethoprimc + PIDs 418 3 0.7 %
Potassium-sparing diuretic +
potassium supplement
380 6 1.6 %
Immunosuppressive agent + PID 353 2 0.6 %
Concurrent administration of 3 or more
PIDsd
1,028 34 3.3 %
ACE inhibitor or angiotensin
antagonist + potassium-sparing
diuretic + potassium supplement
380 10 2.6 %
Immunosuppressive agent +
trimethoprimc plus PID
359 19 5.3 %
ACE inhibitor or angiotensin
antagonist + potassium supplement +
trimethoprimc
245 2 0.8 %
PIDs, Potassium-increasing drugs; ACE, angiotensin converting enzyme
a Patients with at least one serum potassium level measurement within
48 h prior to onset of therapy, with the last value not being hyperkalaemic
(no time restriction for patients with no PID administration)
b Involved the PIDs (in decreasing order of monotherapy leading to
hyperka laemia) : po tass ium supplements , t r imethopr im,
immunosuppressive agents (calcineurin inhibitors), ACE inhibitors,
angiotensin antagonists, potassium-sparing diuretics and direct renin
inhibitors
c Trimethoprim is part of the combination antibiotic cotrimoxazole
(sulfomethoxazole and trimethoprim) used as therapy or prophylaxis for
certain infections
d Concurrent DDIs with <100 patients exposed were not considered
e Total of patients exposed – sum of patients exposed, as the same patient
might have been considered for two different potassium-increasing DDI
groups if they were not overlapping
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levels. Thirdly, the level of severity of the involved DDIs was
not predictive for the likelihood of developing hyperkalaemia.
This might be due to the frequent usage of the contraindicated
level-1 potassium-increasing DDI (i.e. the combination of
potassium-sparing diuretics with potassium supplements) to
correct a hypokalaemia (Fig. 1) [10] including a high degree
of physician awareness [28]. The agreement on whether these
DDIs should indeed be labelled contraindicated is low [29, 30].
Finally, the results of our study confirmed that specific
patient-related characteristics are associated with the
development of hyperkalaemia. These include moderately or
severely impaired renal function (Fig. 2), diabetes mellitus [6,
31], pulmonary allograft (whichwas associatedwith the highest
risk mainly due to PID combinations of immunosuppressive
agents, trimethoprim and ACE inhibitor) [32, 33], female
gender (confirming another analysis of gender as a predictor
of drug-induced hyperkalaemia [34]) and elevated serum
potassium level (>4.5 mEq/l) at onset of the DDI.
In contrast to other studies, we were unable to establish an
association between hyperkalaemia during potassium-
increasing DDIs and age or hospitalisation in surgical versus
non-surgical specialties [12].
There are limitations to our analysis. Dosing of PID
prescriptions was not considered. Only DDIs between two
specific drugs were explored. PIDs not listed in the DDI
knowledge base, such as nonsteroidal anti-inflammatory
drugs or heparin, were not taken into account.
The association between the presence of hyperkalaemia
during potassium-increasing DDIs and transfer to the ICU or
death within 2 days was considered to be statistically
significant. However, the positive correlation does not imply
causation, since the relationship is influenced by comorbidities
and therapies. Overall, the risk of developing hyperkalaemia
was low, occurring only in one of 50 potassium-increasing
DDIs in our study. This is in line with other reports [28].
Despite infrequent occurrences, hyperkalaemias must be
detected in order to avoid severe complications. Clinical decision
support systemsmay help the prescribing physicians to adjust the
therapy early. However, unspecific alerts will lead to alert fatigue
[7–9]. The results of our study improve our understanding of
factors associated with hyperkalaemia [12] and add physician-
related factors, which may help to design more specific alerts.
Table 3 Correlation of death, transfer to intensive care unit and length of
stay with the presence and absence of hyperkalaemia during potassium-
increasing drug–drug interactions
Effect Patients with
hyperkalaemia during
potassium-increasing
DDIs
Patients without
hyperkalaemia during
potassium-increasing DDIs
Death* 5/103 (4.9 %)a 50/5,506 (0.9 %)b
Transfer to
ICU*
9/103 (8.7 %)a 245/5,506 (4.5 %)b
Length of
hospitalisa-
tion
(days)**
26.8±26.5c 12.2±13.8c
*Significant increase at p <0.05 (chi-square test); **significant increase at
p <0.001 (Mann–Whitney test)
a Death or transfer to ICU within 2 days of occurrence of hyperkalaemia
bDeath or transfer to ICU during or <2 days after potassium-increasing
DDI
cMean ± standard deviation
No. of concurrent 
PID administrations
% developing
hyperkalaemia
no PIDs
potassium-increasing 
monotherapy
2 concurrent PIDs
≥3 concurrent PIDs
Fig. 2 Occurrences of
hyperkalaemia as a function of the
number of concurrently
administered potassium-
increasing drugs (PIDs)
categorized by the estimated
glomerular filtration rate (GFR);
inclusion and exclusion criteria
based on those of Table 1,
whereby only patients for whom
an GFR estimation was available
were considered. /Symbols Mean,
Lines encompass a 95 %
confidence interval
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Conclusions
Strategies for the prevention of hyperkalaemia during
treatment with potassium-increasing drugs should consider
both patient- and physician-related characteristics. Patient-
related factors include impaired renal function, diabetes
mellitus and pulmonary allograft. Risk factors associated with
medication include a higher number of concurrently
administered PIDs and a longer DDI duration. Physician-
related factors include undetermined or elevated serum
potassium levels before the initiation of treatment and
inadequate frequency of potassium monitoring during DDIs.
Therefore, the systematic measuring of serum potassium
levels before therapies involving potassium-increasing DDIs
are prescribed and periodic monitoring are essential for
reducing the risk of hyperkalaemia.
Disclosure of conflict of interests None.
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